Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2016-03-08

FDA Approved: ENSTILAR — Supplemental Application (LEO Pharma Inc.)

View source ↗

Summary

The FDA approved a supplemental labeling application for ENSTILAR (calcipotriene and betamethone dipropionate) from LEO Pharma Inc., resulting in changes to the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Enstilar (calcipotriene; betamethasone dipropionate)

Snippet

SUPPL AP for ENSTILAR (CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE)